For patients receiving Opdivo plus Opdualag, the 12-, 24- and 36-month progression-free survival rates were 48%, 38% and 31%, respectively. Overall survival rates were 77%, 62% and 54%, at these time points, respectively, with a 48-month overall survival rate of 52%.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic non-small cell ...

OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.

How does OPDIVO work? OPDIVO can bind to the PD-1 receptor on T cells and block the interaction with PD-L1/PD-L2. This prevents cancer cells from disguising themselves and allows your T cells to be active and attack cancer cells again.

Immunotherapy is a lung cancer treatment. It does not cure stage 4 lung cancer, but it may help patients live longer. Stage 4 lung cancer (also called metastatic lung cancer) is lung cancer that has spread (metastasized) to other parts of the body outside the lungs, such as the brain, bones, and liver.

OS: The median OS was 47.0 months for intermediate- and poor-risk patients treated with Opdivo plus Yervoy versus 26.6 months with sunitinib (Hazard Ratio [HR] 0.68; 95% Confidence Interval [CI]: 0.58 to 0.81), and five-year survival rates were 43% and 31%, respectively.

Opdivo approved as first immunotherapy for first-line advanced gastric cancer in China. Opdivo is now the first and only immunotherapy for the first-line treatment of advanced gastric cancer in China.

MANUFACTURING LOCATIONS The final formulated product will be manufactured, filled, labeled, and packaged at Bristol-Myers Squibb Holdings Pharma, Ltd. Liability Company, in Manatí, Puerto Rico. You may label your product with the proprietary name OPDIVO and will market it in 40 mg and 100 mg single-use vials.

The most common treatments are surgery, chemotherapy, and radiation.

Common Types of Cancer Treatment

• Surgery: An operation where doctors cut out tissue with cancer cells.
• Chemotherapy: Special medicines that shrink or kill cancer cells that we cannot see.
• Radiation therapy: Using high-energy rays (similar to X-rays) to kill cancer cells.

In general, a positive response to immunotherapy is measured by a shrinking or stable tumor. Although treatment side effects such as inflammation may be a sign that immunotherapy is affecting the immune system in some way, the precise link between immunotherapy side effects and treatment success is unclear.

Opdivo, approved for both melanoma and lung cancer, is priced at $12,500 a month, or about $150,000 for a year of treatment; patients take the drug until disease progression or unacceptable toxicity. Keytruda, approved for the treatment of metastatic melanoma, will cost about the same.